Strengthen Your Product Value Story One Phase At A Time

August 23, 2017

Addressing evidence generation in a phase-specific manner provides mutually reinforcing benefits: trials contribute to the value argument and the value data inform the design of the trials. In this way, utilizing the best available secondary research to inform primary research can reduce the risk of regulatory and reimbursement rejections.

A phase-dependent approach has potential to cut costs by avoiding investing in riskier assets, utilizing secondary evidence for multiple assets (thereby using resources more efficiently), and creating payer value while simultaneously meeting regulatory requirements.

The best way to plan evidence generation for the value story is from the beginning. But if you didn’t do that already, the sooner you start the better.

Previous Flipbook
Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article
Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article

Next Flipbook
Innovative trial design Health Economics Webinar PPT
Innovative trial design Health Economics Webinar PPT

×

Speak to one of our experts today

First Name
Last Name
Company Name
Title
Country
Tell us how we can help
We'll be in touch shortly!
Error - something went wrong!